-+ 0.00%
-+ 0.00%
-+ 0.00%

AnaptysBio Completes Spin-Off Of First Tracks Biotherapeutics; Anaptys To Now Exclusively Manage Financial Collaborations For Jemperli With GSK And Imsidolimab With Vanda

Benzinga·04/20/2026 13:18:26
Listen to the news
  • Focused on protecting and returning value of Jemperli and imsidolimab royalties to shareholders
  • Launches with virtual model, including limited FTEs and minimal operating expenses, and approximately $140-$145 million in net cash
     

SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a royalty management company, today announced the completion of its spin-off of First Tracks Biotherapeutics, Inc., its former biopharma operations business.

Anaptys will now exclusively manage the financial collaborations for Jemperli with GSK and imsidolimab with Vanda with a focus on protecting and returning the value of its royalties to shareholders.

The taxable spin-off was completed today following the distribution to Anaptys shareholders of one share of First Tracks Bio common stock for every one share of Anaptys common stock owned as of the close of business on April 6, 2026, the record date for the distribution.

Anaptys will continue to trade on Nasdaq under the ticker symbol "ANAB". First Tracks Bio common stock will begin regular-way trading today on the Nasdaq Global Select Market under the symbol "TRAX".